Market Place
Sourcing Support
KBI to Lead Alanis Therapeutics’ Antibody Development
03 Dec 2024 //
BUSINESSWIRE
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
23 Jul 2024 //
CONTRACT PHARMA
KBI Biopharma Extends Contract After Successful FDA Inspection
23 Jul 2024 //
BUSINESSWIRE
KBI Biopharma Names JB Agnus as Chief Business Officer
15 Apr 2024 //
PRESS RELEASE
KBI Biopharma Appoints Jean-Baptiste Agnus As CBO
15 Apr 2024 //
BUSINESSWIRE
KBI Biopharma Strengthens Quality & RA Expertise Appointment of CQO
01 Apr 2024 //
PRESS RELEASE
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise
01 Apr 2024 //
BUSINESSWIRE
KBI Biopharma Welcomes Peter Carbone as Chief Quality Officer
01 Apr 2024 //
BUSINESSWIREINDIA
KBI Biopharma Recognized Leader All Six Categories of the 2024 CDMO Awards
21 Mar 2024 //
PRESS RELEASE
KBI Biopharma and Argonaut Manufacturing Services Forge Strategic Alliance
16 Jan 2024 //
BUSINESSWIRE
KBI Biopharma Appoints Maggie Chen as Site Head of Patriot Park Mammalian cGMP
05 Jan 2024 //
PRESS RELEASE
KBI Bio Appoints Maggie Chen as Site Head of Patriot Park Mammalian Facility
05 Dec 2023 //
BUSINESSWIRE
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb
12 Sep 2023 //
BUSINESSWIRE
KBI Bio Strengthen Leadership and Expertise With Key Executive Appointments
10 Aug 2023 //
BUSINESSWIRE
KBI Biopharma Appoints New Management Team
10 Aug 2023 //
CONTRACT PHARMA
KBI`s Aaron Pilling Discusses KBI PUREplatform Launch at International 2023
28 Jun 2023 //
PRESS RELEASE
KBI`s Leadership Team Discusses Operational Consolidation with Selexis
23 Jun 2023 //
PRESS RELEASE
KBI Biopharma Unveils KBI PUREplatform™
05 Jun 2023 //
BUSINESSWIRE
JSR Life Sciences Announces Operational Consolidation of KBI Bio and Selexis
31 May 2023 //
BUSINESSWIRE
KBI Bio Appoints Marykay Marchigiani as CFO & Sigma Mostafa as CSO
10 May 2023 //
PRESS RELEASE
KBI Biopharma Appoints David Stewart as Site Head of Durham Mammalian Cgmp
24 Apr 2023 //
BUSINESSWIRE
KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO
17 Apr 2023 //
BUSINESSWIRE
KBI Biopharma Releases Inaugural FIH Manufacturing Batch at Switzerland Facility
21 Mar 2023 //
BUSINESSWIRE
KBI Biopharma Announces Subcontract with Mapp on Sudan ebolavirus Treatment
23 Jan 2023 //
BUSINESSWIRE
KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva
21 Dec 2022 //
CONTRACTPHARMA
KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License
20 Dec 2022 //
BUSINESSWIRE
Tim Lowery Appointed Interim CEO of KBI and Selexis
09 Nov 2022 //
PRESS RELEASE
KBI Biopharma and Selexis SA Appoints Abdelaziz Toumi as Chief Business Officer
31 Oct 2022 //
BUSINESSWIRE
Selexis and NexImmune Sign Service Agreement
08 Sep 2022 //
BUSINESSWIRE
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of State-of-the-Art Facility
06 Jul 2022 //
BUSINESSWIRE
KBI Biopharma and Selexis Open an Integrated Biologics Manufacturing Facility
14 Jun 2022 //
BUSINESSWIRE
JSR Life Sciences Appoints Mark W. Womack to Lead KBI Biopharma and Selexis SA
02 May 2022 //
BUSINESSWIRE
KBI Biopharma Opens New Commercial Manufacturing Facility
21 Apr 2022 //
CONTRACTPHARMA
KBI Biopharma Holds Ribbon Cutting for New Commercial Manufacturing Facility
21 Apr 2022 //
BUSINESSWIRE
Oragenics and KBI Biopharma Enter Covid-19 Vaccine Development Partnership
10 Mar 2022 //
CONTRACTPHARMA
Launch of Generium’s Omalizumab Biosimilar Marks Selexis’ 9th Commercial Product
09 Feb 2022 //
BUSINESSWIRE
Hemogenyx, Selexis Will Advance AML CDX Bispecific Antibody to Human Trials
12 Jan 2022 //
BUSINESSWIRE
Benchling rakes in second nine-figure VC haul this year
19 Nov 2021 //
FIERCEBIOTECH
Eurofins DiscoverX Certifies KBI Biopharma
11 Oct 2021 //
CONTRACTPHARMA
Selexis, KBI Biopharma, Immatics Partner to Advance TCR Program
30 Jun 2021 //
CONTRACTPHARMA
Selexis and KBI Biopharma Enter into Agreements with Immatics
29 Jun 2021 //
BUSINESSWIRE
KBI Biopharma, AM-Pharma Enter Manufacturing Agreement
17 Jun 2021 //
CONTRACTPHARMA
KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma
17 Jun 2021 //
BUSINESSWIRE
Selexis SA Appoints Hoffmann-Hecht CBO
02 Jun 2021 //
CONTRACTPHARMA
Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline
23 Mar 2021 //
BUSINESSWIRE
SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies
18 Mar 2021 //
BUSINESSWIRE
Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion
16 Mar 2021 //
BUSINESSWIRE
Selexis, Pandion Enter Antibody Service Agreement
16 Mar 2021 //
CONTRACTPHARMA
Selexis SA and BITT Enter Service Agreement
10 Mar 2021 //
CONTRACTPHARMA
Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service
09 Mar 2021 //
BUSINESSWIRE
Selexis and Boston Immune Technologies and (BITT) Enter Service Agreement
09 Mar 2021 //
BUSINESSWIRE
KBI Biopharma Expands US Operations with New $150 M Manufacturing
01 Dec 2020 //
BUSINESSWIRE
JSR Life Sciences Expands European Footprint
20 Oct 2020 //
CONTRACTPHARMA
Selexis Appoints CBO
10 Jan 2020 //
CONTRACT PHARMA
ZyVersa, Selexis and KBI Enter Devt. and Mfg. Collaboration
06 Sep 2019 //
CONTRACTPHARMA
CDMO KBI picks up cell therapy plant from struggling biotech Opexa
01 Feb 2017 //
FIERCE PHARMA
JSR Acquires KBI Biopharma
03 Mar 2015 //
DCAT CONNECT
